一种半合成的β-1,4-葡聚糖硫酸酯钠的抗凝血特性。
Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
作者信息
Wang Zhao-mei, Li Lin, Li Bing, Guo Si-yuan
机构信息
Institute of Light Industry and Chemical Engineering, South China University of Technology, Guangzhou.
出版信息
Yao Xue Xue Bao. 2006 Apr;41(4):323-7.
AIM
To investigate the anticoagulant efficacy and mechanism of a semi-synthesized sodium beta-1,4-glucan sulfate (Na-MCS).
METHODS
Anticoagulant activity was evaluated by means of coagulation assays in comparison with heparin. The anticoagulant mechanism of Na-MCS was disclosed by inhibitory analysis of the activities of coagulation factors using chromogenic substrates.
RESULTS
0.6 microg x mL(-1) Na-MCS could significantly prolong APTT and TT, but has less effect on PT at an even higher concentration. The dosage of Na-MCS required to double APTT of normal human plasma was 0.7 microg x mL(-1), lower than that of heparin with the activity of 150 u x mg(-1).
CONCLUSION
Na-MCS represented a potent anticoagulation activity in vitro, which matched the efficacy of heparin in a certain range of concentrations. Na-MCS exhibited anticoagulant activity due to inhibition of the coagulation factors IIa and Xa by the mediation of anti-thrombin AT-III.
目的
研究半合成β-1,4-葡聚糖硫酸钠（Na-MCS）的抗凝疗效及机制。
方法
通过凝血试验评估抗凝活性，并与肝素进行比较。使用显色底物通过对凝血因子活性的抑制分析来揭示Na-MCS的抗凝机制。
结果
0.6μg·mL⁻¹的Na-MCS可显著延长活化部分凝血活酶时间（APTT）和凝血酶时间（TT），但在更高浓度时对凝血酶原时间（PT）影响较小。使正常人血浆APTT翻倍所需的Na-MCS剂量为0.7μg·mL⁻¹，低于活性为150 u·mg⁻¹的肝素。
结论
Na-MCS在体外表现出强大的抗凝活性，在一定浓度范围内与肝素疗效相当。Na-MCS通过抗凝血酶AT-III介导抑制凝血因子IIa和Xa而表现出抗凝活性。
Zotero 插件